BIOPHYTIS SA SP/ADR

The sarcopenia market remains largely untapped, with significant unmet medical needs and no approved drug therapies. However, pharmaceutical interest is rising, particularly around muscle-enhancing agents and anti-inflammatory pathways. Regulatory bodies are beginning to recognize sarcopenia as a distinct clinical condition, which may streamline future drug approvals.

Related tickers: BPTSY, TNFA, LPCN.

The article discusses the advancements in gene therapy for Stargardt disease, a genetic eye disorder, and highlights the significant investment and interest in developing long-term treatments. It mentions over 20 companies working on 25+ pipeline drugs to improve the treatment landscape.

Related tickers: BLTE, BPTSY, KPRX.